Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/distention

Clinical and Experimental Rheumatology

Volumn 29, Issue 2 SUPPL. 65, 2011, Pages

  Frech, Tracy ^a   Khanna, D ^b   Maranian, P ^b   Frech, E J ^c   Sawitzke, A D ^a   Murtaugh, M A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Mountain West Gastroenterology   (United States)

Author keywords

Bloating distention; Gas trointestinal involvement; Probiotics; Systemic sclerosis; UCLA SCTC GIT 2.0

Indexed keywords

PROBIOTIC AGENT; ALIGN; CULTURELLE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIFIDOBACTERIUM LONGUM INFANTIS; CLINICAL ARTICLE; DISEASE SEVERITY; EMOTION; FEMALE; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE DISTENSION; LACTOBACILLUS; MALE; PRIORITY JOURNAL; STOMACH DISTENSION; SYSTEMIC SCLEROSIS; ABDOMINAL DISTENSION; BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS; BLOATING; DIARRHEA; DIGESTIVE SYSTEM DISEASE ASSESSMENT; MIDDLE AGED; PILOT STUDY; UNIVERSITY OF CALIFORNIA LOS ANGELES SCLERODERMA CLINICAL TRIAL CONSORTIUM GASTROINTESTINAL TRACT 2.0; YOUNG ADULT;

ADULT; AGED; ANTIFOAMING AGENTS; BIFIDOBACTERIUM; DIETARY SUPPLEMENTS; FEMALE; FLATULENCE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; LACTOBACILLUS; MALE; METAGENOME; MIDDLE AGED; PILOT PROJECTS; PROBIOTICS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79960413156     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. HUNZELMANN N, KRIEG T: Scleroderma: From pathophysiology to novel therapeutic approaches. Exp Dermatol 2010; 19: 393-400.
2. LOCK G, HOLSTEGE A, LANG B, SCHOLMERICH J: Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol 1997; 92: 763-71.
3. KHANNA D, DENTON CP: Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol 2010; 24: 387-400.
4. BOIRIVANT M, STROBER W: The mechanism of action of probiotics. Curr Opin Gastroenterol 2007; 23: 679-92.
5. LAKHAN SE, KIRCHGESSNER A: Gut inflammation in chronic fatigue syndrome. Nutr Metab (Lond) 2010; 7: 19.
6. OHLAND CL, MACNAUGHTON WK: Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 298: G807-19.
7. GARRETT WS, GORDON JI, GLIMCHER LH: Homeostasis and inflammation in the intestine. Cell 2010; 140: 859-70.
8. SUTAS Y, HURME M, ISOLAURI E: Down-regulation of anti-cd3 antibody-induced il-4 production by bovine caseins hydrolysed with lactobacillus gg-derived enzymes. Scand J Immunol 1996; 43: 687-9.
9. MIKELSAAR M, STSEPETOVA J, HUTT P et al.: Intestinal lactobacillus sp. Is associated with some cellular and metabolic characteristics of blood in elderly people. Anaerobe 2010; 16: 240-6.
10. MANDEL DR, EICHAS K, HOLMES J: Bacillus coagulans: A viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern Med 2010; 10: 1.
11. DROUAULT-HOLOWACZ S, BIEUVELET S, BURCKEL A, CAZAUBIEL M, DRAY X, MARTEAU P: A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol 2008; 32: 147-52.
12. KHANNA D, HAYS RD, MARANIAN P et al.: Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009; 61: 1257-63.
13. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Sub-committee for scleroderma criteria of the american rheumatism association diagnostic and therapeutic criteria committee. Arthritis Rheum 1980; 23: 581-90.
14. HAYES, RD: Reliability and validity (including responsiveness). In: FAYERS P HR (Ed.) Assessing quality of life in clinical trials. New York: Oxford, 2005: pp. 25-39.
15. VERNA EC, LUCAK S: Use of probiotics in gastrointestinal disorders: What to recommend? Therap Adv Gastroenterol 2010; 3: 307-19.